OP80 Cost-Utility Analysis Of Glucocorticoids Versus Standard Care For The Treatment Of Knee Osteoarthritis – Health Payer Perspective
Danielle Stringer, Magdalena Moshi, Alvin Atlas, John Rathbone, Thomas Vreugdenburg · 2025
Read OP80 Cost-Utility Analysis Of Glucocorticoids Versus Standard Care For The Treatment Of Knee Osteoarthritis – Health Payer Perspective by Danielle Stringer, Magdalena Moshi, Alvin Atlas, John Rathbone, Thomas Vreugdenburg (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768674.txt.
Description
Danielle Stringer and co-authors weigh whether steroid shots into the knee are worth their cost for knee arthritis in Switzerland. The shots are a common stopgap for pain. A world search found only one prior cost study, so the team built their own from the health payer's view.
Their model ran six months and counted a single shot, since trials show pain relief at one month but not beyond. They compared costs against quality-adjusted life years gained. Checks that varied the inputs tested how firm the answer was. Such cost work helps payers decide where a short-lived gain justifies the bill.
Catalog record
| CREATOR | Danielle Stringer, Magdalena Moshi, Alvin Atlas, John Rathbone, Thomas Vreugdenburg |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |